トルコで最高の骨髄移植術医師 - トップ27名の医師

Experience

• 1990 - 1994 – General Practitioner
• 1994 - 2001 – Research Assistant, Erciyes University, Faculty of Medicine
• 2001 - 2006 – Assistant Professor, Internal Medicine/Hematology, Erciyes University, Faculty of Medicine
• 2006 - 2011 – Associate Professor, Internal Medicine/Hematology, Erciyes University, Faculty of Medicine
• 2011 - 2019 – Professor, Internal Medicine/Hematology, Erciyes University, Faculty of Medicine

Professional Memberships

• Turkish Society of Hematology
• European Group for Blood and Marrow Transplantation (EBMT)
• Hematologic Oncology Association
• Antalya Medical Chamber

アナドル骨髄移植センターの創設者であるグルバシュ教授は、トルコ第1位の血液腫瘍専門医として評価されています。

• 骨髄移植のみを専門とする
• シアトルのフレッド・ハッチンソンをはじめとする主要センターで研鑽を積む
• 2005年より腫瘍内科部長を務める
• Türk Hematoloji Derneği（トルコ血液学会）会員

Mustafa Solak氏は、骨髄移植を要する複雑な癌症例を専門とし、ハジェテペ大学癌研究所およびMDアンダーソン癌センターにて研鑽を積んでいる。

• 乳癌、精巣癌、卵巣癌を専門とする
• 米国トップクラスの癌センターにてフェローシップ研修を修了
• ヒサール・ホスピタル・インターコンチネンタルに勤務

Education:

2015

Dokuz Eylül University, Medical Faculty, Internal Medicine and Hematology 

2010

Dokuz Eylül University, Medical Faculty, Internal Medicine 

2005

Hacettepe University, Medical Faculty,

Experience:

2024 – 

Istanbul Florence Nightingale Hospital

2017 – 2024

Bağcılar Medipol University Hospital

2017 – 2017

Fırat University

2015 - 2017

Fırat University

2014 - 2015

Mayo Clinic

Publications:

18 Articles Published in International Peer-Reviewed Journals

26 Abstracts and Books Presented at International Scientific Conferences

7 Articles Published in National Peer-Reviewed Journals

51 Abstracts Presented at National Scientific Conferences

Prof. Dr. Ceyhun Bozkurt is a respected Pediatric Hematologist-Oncologist. He is known for his work in childhood blood disorders and cancers. He graduated from Cerrahpaşa Faculty of Medicine. He holds specializations in both Pediatrics and Pediatric Oncology. Since 2019, he has been Professor and Clinical Director at Bahçelievler Medical Park Hospital. He also serves as Vice Director of the Stem Cell Transplant Unit.

Dr. Bozkurt has published over 40 peer-reviewed articles. He is recognized for his work in leukemia, bone marrow transplantation, and stem cell therapy. He is a member of organizations such as SIOP and EBMT. His memberships show his dedication to high standards in clinical care and research.

ドクター ベトゥル・タビル は、小児血液腫瘍学の教授であり、小児骨髄移植における世界的な専門家です。

タビル医師が患者から信頼される理由：

• 卓越した治療実績を持つ医師 ― 白血病の小児500名以上の治療に成功し、100名以上の小児に骨髄移植を実施しています。
• 小児における極めて稀な血液疾患の専門家：先天性赤芽球性ポルフィリン症、免疫不全症、遺伝性血液疾患。
• 受賞歴のある研究者 ― 小児血液がん治療における顕著な業績に対し、トルコ血液学会賞を受賞しています。
• 国際学術誌における150本以上の論文および1,700件以上の被引用数を誇り、新たな治療法の開発を継続的に行っています。
• 小児における悪性および非悪性疾患に対する高度な骨髄移植の第一人者です。
• 28年にわたる主要医療機関での経験 ― ハセッテペ大学、Ankara Children's Hospital、Memorial Şişli。
• オンライン診療を実施 ― 自宅にいながら、卓越した小児血液専門医の専門的見解を得ることが可能です。

学歴・経歴

• エーゲ大学医学部、1978年
• 小児科専門医取得、1982年
• 小児腫瘍学専門医取得、2002年（EU医学部）
• 小児血液腫瘍学、2012年（EU医学部）
• テペジックEAH 副科長、1988年
• テペジックEAH 科長、1993年
• 准教授資格取得、1995年
• 教授就任、2002年
• エーゲ大学医学部、講師、1998年〜2022年
• ヨーロッパ医学部、小児科学教室、2009年〜2018年
• テペジック教育計画・調整委員会委員（1993年〜1998年）
• SSIテペジック病院倫理委員会委員長（1996年〜1998年）
• トルコ小児血液学会「骨髄移植ワーキンググループ 共同委員長」（2002年〜2006年）
• トルコ小児血液学会「骨髄移植ワーキンググループ」（2006年〜2008年）
• トルコ小児血液学会 — 骨髄移植オンラインデータ登録システム担当、2007年〜現在
• エーゲ大学再生医療・幹細胞委員会委員長、2011年〜2021年

学術団体会員

• トルコ医師会、イズミル支部およびコジャエリ支部
• トルコ国立小児科学会 — イズミル
• 欧州骨髄移植グループ（EBMT）；エーゲ大学小児骨髄移植部門は、2007年6月に欧州骨髄移植グループ（EBMT）より認定を受けた。
• トルコ小児血液学会 — 理事会メンバー、2期（2005年〜2009年）
• トルコ血液学会 — 理事会メンバー、2期（2001年〜2005年）
• トルコ小児腫瘍学会
• 骨髄移植財団（KITVAK）評議員会メンバー

創設した部門

1- SSIテペジック病院 小児腫瘍科（1990年）
2- SSIテペジック病院 小児骨髄移植部門（1992年）
3- ヨーロッパ医学部 小児骨髄移植部門（1998年）
4- 小児研究雑誌 創刊者、2014年；SCI申請は2022年に提出

設立に貢献した移植部門

1. イズミルBUÇ病院 小児骨髄移植部門（2019年）
2. ÜmraniyeEAH 小児骨髄移植部門（2020年）
3. カーヌーニー・スルタン・スレイマンEAH 小児骨髄移植部門（2020年）（チャム・サクラEAH骨髄移植部門へ移管）

受賞歴

• 骨髄幹細胞移植患者における血栓症関連パラメータ、小児血液学会議、トラブゾン、2003年
• 幹細胞におけるCD133抗原：小児血液学会議2005年 研究賞
• 発熱性好中球減少症患者におけるToll様受容体の役割、最優秀ポスター賞、トルコ血液学会議2008年、チェシュメ・イズミル
• 小児における造血幹細胞移植の全国的活動 — 口頭発表、第2位、トルコ血液学会造血幹細胞移植会議、2022年、アンタルヤ

著作・出版物

Kansoy S.「骨髄・幹細胞移植。小児の健康と疾患」、第1版、EU医学部出版、1999年、イズミル

Kansoy S. 重症型サラセミアIIIにおける骨髄移植。エーゲ・サラセミアデーズ書籍、2000年、イズミル

Kansoy S. トルコにおける小児KIT移植センターの基準。小児急性白血病、アンタルヤ2000年：73-5

Kansoy S. 小児における晩期副作用。Bone Marrow Transplantation Journal of Turkish Clinics 特別号、2003年

Kansoy S. 骨髄・幹細胞移植における幹細胞の応用。小児腫瘍看護学テキスト、イズミル、2005年

Kansoy S. 幹細胞源としての臍帯血。幹細胞特別号、Turkish Clinics、2008年

Kansoy S. リンパ腫における幹細胞移植。一般小児科書籍、Enver Hasanoğlu教授編、2009年

Kansoy S.、Aksoylar S. 小児における骨髄移植。小児科学、2014年および2017年

Kansoy S. 横紋筋肉腫。小児科学、2014年および2017年

Kansoy S. 臨床所見に基づく腫瘍性疾患を有する小児へのアプローチ。小児科学、2014年および2017年

11. Çetingül N.、Kansoy S.、Kantar M. 腫瘍性疾患。小児科学（A. Kura編）、641-672、エーゲ大学出版、イズミル、1999年。（1.05点）

Kansoy S.、M. Kantar. 頭部・顔面・眼の診察。義肢装具士の身体診察と症状に関する情報（A. Kura編）

Kantar M. 腫瘍学における代謝性緊急症の問題。小児期における腫瘍学的緊急症と支持療法（N. Çetingül、S. Kansoy編）、15-24、Meta Basım、イズミル、2003年

トルコにおける臍帯血移植。HEMATOLОГ、2016年

Kansoy S. 小児中枢神経系腫瘍、小児科学、2014年および2017年

小児急性骨髄芽球性白血病およびその治療。小児腫瘍学教科書、Poplack's Turkish版、2020年

小児における造血幹細胞移植の全国的活動、2020年

小児における幹細胞移植の適応、Turkish Clinics — 国際版、2020年

多数の国際学術誌における研究論文・原著論文に加え、インパクトファクターの高い一部の学術誌において国際多施設共同研究にも参加している。

Dr. Toluy Özgümüş has graduated from Istanbul University, Cerrahpaşa Faculty of Medicine in 2008 and completed his internal medicine specialty training at Haydarpaşa Numune Training and Research Hospital between 2009 and 2013. He received his Hematology subspecialty training at Marmara University Hematology Department between 2014-2017; He performed his compulsory service at Kars Harakani State Hospital between 2017-2019. He worked at Sancaktepe Şehit Prof. Dr. Ilhan Varak Training and Research Hospital between 2019-2023.

He is experienced in the field of bleeding and coagulation disorders, especially coagulation disorders (thrombophilia), and has dealt with the diagnosis and treatment of more than 1000 patients. Since he worked in the pandemic hospital of the Anatolian side of Istanbul during the pandemic period, he has extensive experience in the hematological findings of Covid-19 infection and the management of Covid-19 infection in hematological diseases. Hundreds of patient experiences are available in the diagnosis of myeloproliferative diseases such as Polycythemia Vera and Essential Thrombocytosis, in their differentiation from blood cell elevations due to other frequently confused causes, and in their treatment. He has experience in the diagnosis and all treatment processes of rare hematological cancers such as multiple myeloma, acute and chronic leukemias, lymphomas and histiocytosis, as well as bone marrow transplantation.

MEDICAL INTERESTS 

Clotting Disorders (Thrombophilia)

Bleeding Disorders

Myeloproliferative Diseases

Anemias (Anemia)

Acute and Chronic Leukemias

lymphomas

Bone marrow transplantation

Prof. Dr. Şebnem İzmir Güner was born in 1970 in Istanbul and took her first steps in her medical career at Istanbul University Faculty of Medicine. Successfully completing her undergraduate and medical education here between 1987-1993, Güner received her internal medicine specialty training at Istanbul University Cerrahpaşa Faculty of Medicine from 1995 to 2000. Deepening her interest in hematology, Prof. Dr. Güner completed her hematology subspecialty training at Cerrahpaşa Faculty of Medicine again between 2003-2006, solidifying her expertise in this field.
Prof. Dr. Güner’s professional journey began as an internal medicine specialist at Istanbul Education and Research Hospital from 2000 to 2003. She established the Hematology Clinic at the same hospital from 2006 to 2010 and served as the responsible physician. Here, she developed innovative approaches in the treatment of patients and made significant contributions to the field of hematology. From 2010 to 2016, she established the Hematology Clinic, Therapeutic Apheresis, and Adult Bone Marrow Transplantation Center at Medicalpark Bahçelievler Hospital and served as the responsible physician. During this period, she conducted studies that set national and international standards in the field of hematology.
Between 2016-2018, Prof. Dr. Güner took on similar roles at Şişli Kolon International Hospital, where she was also the founder and responsible physician of the Hematology Clinic, Therapeutic Apheresis, and Adult Bone Marrow Transplantation Center. Güner, who became an associate professor in 2017, obtained her professorship title in 2023. Between 2019-2024, she worked at Memorial Şişli Hospital in the Hematology Clinic, Therapeutic Apheresis, and Adult Bone Marrow Transplantation Center.
Prof. Dr. Şebnem İzmir Güner is recognized for her scientific contributions, with over 19 articles published in international peer-reviewed journals. Additionally, she has over 18 articles published in national peer-reviewed journals and 51 presentations at national scientific meetings that have been published in proceedings books. She has also made a name for herself in the academic world with over 18 presentations at meetings and published in proceedings books. Güner, who has held positions on the boards of domestic hematology associations and has active memberships, has crowned her success with more than three awards given at universities and conferences.
Prof. Dr. Şebnem İzmir Güner, who speaks English and German, is also recognized as an educator. In this capacity, she has contributed to the training of young doctors in the field of hematology, providing education to research assistant doctors and students.
Prof. Dr. Şebnem İzmir Güner has established a respected place in the field of hematology with her achievements and scientific contributions throughout her professional life, continuing her career as a physician who inspires her patients and colleagues.

MEDICAL INTERESTS

• Leukemia
• Lymphoma
• Multiple myeloma
• Bone marrow transplantation
• Anemia
• Bleeding and coagulation disorders
• Hemophilia

Prof. Müge Gökçe is a pediatric hematologist and cancer specialist based in Turkey with expertise in bone marrow transplantation. She has held positions in various hospitals since 2001 and holds degrees in general medicine, pediatrics, and pediatric hematology and oncology. She is a member of the Turkish Hematology Association, the Turkish Society of Pediatric Hematology, and the European Society for Blood and Marrow Transplantation.

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

Education and Expertise

Ankara University Faculty of Medicine - Medical Education

Gazi University Faculty of Medicine Department of Internal Medicine - Internal Medicine - Specialization

Gazi University Faculty of Medicine Department of Hematology - Hematology - Subspecialty

Duke University Bone Marrow Transplantation Center - Stem Cell Transplantation Training

Fred Hutchinson Cancer Research Center Seattle - Stem Cell Transplant Training

Experience

Duke University-Durham North Carolina Bone marrow transplantation program 2001, cord blood transplant

Fred Hutchinson Cancer Research Center Bone Marrow Transplantation program Seattle 2002, unrelated stem cell transplant

Founder and manager of Gazi University Faculty of Medicine Adult Stem Cell Transplant Unit 2003-2014

Gazi University Faculty of Medicine, Head of Hematology Department 2008-2014

Gazi University Faculty of Health Sciences Dean (founder) 2008-2012

Professional Memberships

Turkish Hematology Association





Bilimsel Yayınları

1.    Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.
    Bone Marrow Transplant. 2017 Jul;52(7):1081. doi: 10.1038/bmt.2017.86
2.    Deger SM, Erten Y, Suyani E, Aki SZ, Ulusal Okyay G, Pasaoglu OT, Pasaoglu H, Arinsoy T, Turkoz Sucak G. Early Diagnostic Markers for Detection of Acute Kidney Injury in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Exp Clin Transplant. 2017 Apr 14. doi: 10.6002/ect.2016.0161. [Epub ahead of print]
3.    Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A, Tuğlular T, Drach J, Armbrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol. 2017 Jul;178(1):61-71. doi: 10.1111/bjh.14637. Epub 2017 Apr 6
4.    Özkurt ZN, Sucak GT, Akı ŞZ, Yağcı M, Haznedar R.Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Cancer Invest. 2017 Mar 16;35(3):195-201. 
5.    Aslan D, Türköz-Sucak G, Percy MJ. Recessive congenital methemoglobinemia in immediate generations.Turk J Pediatr. 2016;58(1):113-115
6.    Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant. 2017 Feb;52(2):209-215. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1081.
7.    Pamukcuoglu M, Acar K, Celik B, Akyurek N, Pepeler MS, Sucak GT. Peripheral and bone marrow CD34+ cell levels on chronic myeloproliferative disease. Hematology. 2017 Mar;22(2):74-80. 
8.    van Gorkom G, Finel H, Giebel S, Pohlreich D, Shimoni A, Ringhoffer M, Sucak G, Schaap N, Dreger P, Sureda A, Schouten HC. Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. J Clin Apher. 2016 Sep 10. doi: 10.1002/jca.21506. [Epub ahead of print]
9.    Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger LA, Oechsle K, Schumacher K, Kanfer E, Bourhis JH, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Bone Marrow Transplant. 2016 Mar;51(3):384-90. 
10.    Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socié G, Eder M, Bonifazi F, Bunjes D, Vigouroux S, Michallet M, Stelljes M, Zuckerman T, Finke J, Passweg J, Yakoub-Agha I, Niederwieser D, Sucak G, Sengeløv H, Polge E, Nagler A, Esteve J, Mohty M; Acute Leukemia Working Party of EBMT. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2016 Mar;51(3):351-7. 
11.    Marchand T, Lamy T, Finel H, Arcese W, Choquet S, Finke J, Huynh A, Irrera G, Karakasis D, Konopacki J, Lambert J, Michieli M, Schouten HC, Schroyens W, Sucak G, Tischer J, Vandenberghe E, Dreger P. Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation. Leukemia. 2016 May;30(5):1201-4
12.    Köktürk N, Yıldırım F, Aydoğdu M, Akı ŞZ, Yeğin ZA, Özkurt ZN, Suyanı E, Kıvılcım Oğuzülgen İ, Türköz Sucak G. Is It Possible to Predict Pulmonary Complications and Mortality in Hematopoietic Stem Cell Transplantation Recipients from Pre-Transplantation Exhaled Nitric Oxide Levels? Turk J Haematol. 2016 Mar 5;33(1):34-40. 
13.    Barğı G, Güçlü MB, Arıbaş Z, Akı ŞZ, Sucak GT. Inspiratory muscle training in allogeneic hematopoietic stem cell transplantation recipients: a randomized controlled trial. Support Care Cancer. 2016 Feb;24(2):647-659
14.    Camcıoğlu B, Boşnak-Güçlü M, Karadallı MN, Akı ŞZ, Türköz-Sucak G. The Role of Inspiratory Muscle Training in Sickle Cell Anemia Related Pulmonary Damage due to Recurrent Acute Chest Syndrome Attacks.Case Rep Hematol. 2015;2015:780159. doi: 10.1155/2015/780159. Epub 2015  Apr 28.
15.     Fox CP, Boumendil A, Schmitz N, Finel H, Luan JJ, Sucak G, Blaise D, Finke J, Pflüger KH, Veelken H, Gorin NC, Poiré X, Ganser A, Dreger P, Sureda A. High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in Western patients; a study from the European Society for Blood and Marrow Transplantation. Leuk Lymphoma. 2015 Apr 22:1-20. 
16.    Akı ŞZ, Suyanı E, Cengiz M, Özenirler S, Elbeğ Ş, Paşaoğlu H, Sucak GT. Association between Plasma Endothelin-1, Transforming Growth Factor-β, Fibroblast Growth Factor, and Nitric Oxide Levels and Liver Injury in Hematopoietic Stem Cell Transplantation Recipients with Persistent Iron Overload after Transplantation. Biol Blood Marrow Transplant. 2015 May;21(5):948-953.
17.    Beksaç M, Waage A, Bringhen S, Kristinsson SY, Sucak G, Gimsing P, Giulia L, Tuglular TF, Juliusson G, Turesson I, Palumbo A. Does Low Molecular Weight Heparin Influence The Anti-Myeloma Effects Of Thalidomide? A Retrospective Analysis On Data From The GIMEMA, Nordic and Turkish Myeloma Study Groups Acta Haematologica 2015 Mar 24;133(4):372-380
18.    Pepeler MS, Acar K, Güzel Tunçcan Ö, Uluoğlu Ö, Kalkancı A, Atalar H, Kılıç K, Türköz Sucak G. A proven case of cutaneous rhizopus infection presenting with severe limb pain very soon after induction treatment in a patient with acute lymphoblastic leukemia. Case Rep Hematol. 2015;2015:285360. doi: 10.1155/2015/285360. Epub 2015 Feb 15.
19.    Yegin ZA, Iyidir OT, Demirtaş C, Suyanı E, Yetkin I, Paşaoğlu H, Ilhan C, Sucak GT. The interplay among iron metabolism, endothelium and inflammatory cascade in dysmetabolic disorders. J Endocrinol Invest. 2014 Sep 23. [Epub ahead of print]
20.    Tanase A, Schmitz N, Stein H, Boumendil A, Finel H, Castagna L, Blaise D, Milpied N, Sucak G, Sureda A, Thomson K, Vandenberghe E, Vitek A, Dreger P. Allogeneic and Autologous Stem Cell Transplantation for hepatosplenic T cell lymphoma: A retrospective study of the EBMT Lymphoma Working party. Leukemia. 2014 Sep 19. doi: 10.1038/leu.2014.280. [Epub ahead of print]
21.    Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Göker H, Başlar Z, Ferhanoglu B. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol. 2014 Sep 18. [Epub ahead of print]
22.    Aygencel G, Türkoğlu M, Türköz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2014 Aug;29(4):618-26.
23.    Pamukçuoğlu M, Emmez H, Tunçcan OG, Oner AY, Cırak MY, Senol E, Sucak GT. Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections. Hematology. 2014 Apr;19(3):158-62. 
24.    Kadir Acar, Şahika Zeynep Akı, Zübeyde Nur Özkurt, Gülendam Bozdayı, Seyyal Rota, Gülsan Türköz Sucak Factors Associated with Cytomegalovirus Reactivation Following Allogeneic Hematopoietic Stem Cell Transplantation: Human Leukocyte Antigens Might Be Among the Risk Factors Turk J Haematol. 2014 Sep 5;31(3):276-285
25.    Abdülkerim Yıldız, Merih Kızıl Çakar, Elif Suyanı, Gülsan Türköz Sucak A Systemic Lupus Erythematosus Patient with Isolated Neutropenia and Diminished Expression of CD55 and CD59 Similar to Paroxysmal Nocturnal Hemoglobinuria doi: 10.4274/Tjh.2013.0318   Pages 323 – 324
26.    Suyanı E, Sucak GT, Akyürek N, Sahin S, Baysal NA, Yağcı M, Haznedar R. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann Hematol. 2013 May;92(5):669-77
27.    Akyol A, Nazlıel B, Batur Caglayan HZ, Oner Y, Sucak GT. Recurrent Transient Ischemic Attacks in a Patient with POEMS Syndrome. Case Rep Neurol Med 2014:158471
28.    Boyacı N, Aygencel G, Turkoglu M, Yegin ZA, Acar K, Sucak GT. The intensive care management process in patients with hematopoietic stem cell transplantation and factors affecting their prognosis. Hematology. 2014 Sep;19(6):338-45
29.    Merve Pamukcuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak. Non-Leukemic Granulocytic Sarcoma Presenting with Multiple Skin Nodules and a Retroperitoneal Mass. Turk J Hematol 2013;30:81-82
30.    Merve Pamukçuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak A Rare Case of Acute Leukemia Relapsing with a Granulocytic Sarcoma Causing Ectopic Pregnancy Indian Journal of Hematology and Blood Transfusion April 2013
31.    Keser I, Suyani E, Aki SZ,  Sucak AG. The positive impact of regular exercise program on stem cell mobilization prior to autologous stem cell transplantation. Transfus Apher Sci. 2013 Jul 6. doi:pii: S1473-0502(13)00205-X. 10.1016/j.transci.2013.06.007. [Epub ahead of print]
32.    Buyukasik Y, Acar K, Kelkitli E, Uz B, Serefhanoglu S, Ozdemir E, Pamukcuoglu M, Atay H, Bektas O, Sucak GT, Turgut M, Aksu S, Yagci M, Sayınalp N, Ozcebe OI, Goker H, Haznedaroglu IC.  Hyper-CVAD Regimen in Routine Management of Adult Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study. Acta Haematol 2013 Jun 19;130(3):199-205.
33.    Yaşar DG, Suyanı E, Özenirler S, Sucak GT. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.Transplant Proc. 2013 Mar;45(2):833-4.
34.    Keser I, Suyani E, Yosmaoglu HB, Aki SZ, Sucak AG. Acute physiological responses to physiotherapy applications pre and post autologous stem cell transplantation: an experimental study. Hematology. 2014 Apr;19(3):136-40.
35.    Yağcı M, Yegin ZA, Akyürek N, Kayhan H, Ozkurt ZN, Sucak GT, Haznedar R. TCTP/HRF pathway and angiogenesis: a feasible intercourse in chronic lymphocytic leukemia. Leuk Res. 2013 Jun;37(6):665-70.
36.    Sucak GT, Cakar MK, Suyanı E, Akı Z, Altındal SE, Acar K. Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey. Hematology. 2013 Sep;18(5):269-76.
37.    Türkoğlu M, Erdem GU, Suyanı E, Sancar ME, Yalçın MM, Aygencel G, Akı Z, Sucak G.Acute respiratory distress syndrome in patients with hematological malignancies. Hematology. 2013 May;18(3):123-130.
38.    Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A. Paternity wishes in long-term survivors after allogeneic hematopoietic SCT. A study of the late effects working party of the EBMT. Bone Marrow Transplant. 2013 Jun;48(6):878-9.
39.    Çakar MK, Suyani E, Sucak GT, Altindal Ş, Aki SZ, Acar K, Yağci M, Rota S, Özenirler S. HBV-related events after allogeneic hematopoetic stem cell transplantatıon in a center from Turkey. Ann Hematol. 2013 Mar;92(3):395-402.
40.    Akı ŞZ, Suyanı E, Bildacı Y, Çakar MK, Baysal NA, Sucak GT. Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation. Clin Transplant. 2012 Sep-Oct;26(5):E513-2.
41.    Akı SZ, Pamukçuoğlu M, Bağrıaçık Ü, Sucak GT. Encephalopathy: an unusual neurologic complication of autologous hematopoietic stem cell transplant in patients with multiple myeloma with renal failure.Leuk Lymphoma. 2013 Apr;54(4):894-6.
42.    Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A; Late Effects Working Party of the EBMT. Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2013 Mar;98(3):339-45.
43.    Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld PSafety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013 Jan;98(1):87-94.
44.    Aydoğdu M, Ozyilmaz E, Köktürk N, Yeğin ZA, Özkurt ZN, Aki ZS, Sucak G. Is there any relationship between pulmonary function tests and post-transplant complications of allogeneic hematopoetic stem cell transplantation? Minerva Med. 2012 Jun;103(3):189-98.
45.    Suyanı E, Altındal Ş, Akı Ş, Sucak GT. Does fludarabine increase the incidence of sinusoidal obstruction syndrome when combined with Bu/Cy during conditioning? Clin Transplant. 2012 Mar-Apr;26(2):E85-6.
46.    Sucak GT, Yaşar DG, Yegin ZA, Ergün MA, Ozkurt ZN, Aki ŞZ, Güntekin S. The prognostic role of hemochromatosis H63D allele in allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2012 Aug;91(8):1281-7.
47.    Suyanı E, Sucak GT, Erten Y, Cakar MK, Ulusal G, Yağcı M, Haznedar R. Evaluation of multiple myeloma patients presenting with renal failure in a university hospital in the year 2010. Ren Fail. 2012;34(2):257-62.
48.    Sucak GT, Suyanı E, Baysal NA, Altındal Ş, Çakar MK, Akı ŞZ, Yeğin ZA, Şanlıer N.The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing allogeneic stem cell transplantation with busulfan-cyclophosphamide conditioning. Int J Hematol. 2012 Jan;95(1):95-101.
49.    Bağrıaçık EU, Yaman M, Haznedar R, Sucak G, Delibasi T. TSH-induced gene expression involves regulation of self-renewal and differentiation-related genes in human bone marrow-derived mesenchymal stem cells.J Endocrinol. 2012 Feb;212(2):169-78.
50.    Elif Suyanı, Zeynep Akı, Zeynep Arzu Yeğin, Gülsan Türköz Sucak. Bortezomib-Associated Severe Orthostatic Hypotension and Hyponatremia Turk J Hematol 2012; 29: 301-302.
51.    Zeynep Arzu Yegin, Gülsan Türköz Sucak, Gonca Erbaş, Münci Yağcı ARA-C associated pulmonary toxicity. Turk J Hematol 2011; 28: 81-3.
52.    Turkoglu M, Mirza E, Tunçcan OG, Erdem GU, Dizbay M, Yağcı M, Aygencel G, Türköz Sucak G. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care. 2011 Oct; 26(5):460-7.
53.    Akı SZ, Paşaoğlu H, Yeğin ZA, Suyanı E, Demirtaş CY, Ozkurt ZN, Yağcı M, Sucak GT. Impact of prohepcidin levels and iron parameters on early post-transplantation toxicities.Hematology. 2011 Sep;16(5):284-90.
54.    Yenicesu I, Sucak G, Dilsiz G, Akı SZ, Yeğin ZA. Hematopoietic stem cell transplantation in a very high risk group of patients with the support of granulocyte transfusion. Indian J Hematol Blood Transfus. 2011 Sep;27(3):146-51.
55.    Tunçcan ÖG, Aki ŞZ, Akyürek N, Sucak G, Şenol E. Isolated cutaneous aspergillosis in an acute lymphoblastic leukemia patient after allogeneic stem cell transplantation.J Infect Dev Ctries. 2011 May 28;5(5):406-9.
56.    Rota S, Fidan K, Bozdayı G, Dalgıç A, Fidan I, Sucak G, Müderris T. [Investigation of BK and JC virus DNA positivities by real-time polymerase chain reaction in the clinical samples of patients with high risk].Mikrobiyol Bul. 2011 Apr;45(2):280-7.
57.    Suyanı E, Yağcı M, Sucak GT. Complete remission with a combination of lenalidomide, cyclophosphamide and prednisolone in a patient with incomplete POEMS syndrome. Acta Haematol. 2011;126(4):199-201.
58.    Sucak GT, Özkurt ZN, Suyanı E, Yaşar DG, Akdemir ÖÜ, Akı Z, Yeğin ZA, Yağcı M, Kapucu ÖL. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol. 2011 Nov;90(11):1329-36.
59.    Ljungman P,  de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, Cordonnier C, Einsele H, Gonzalez-Vicent M, Espigado I, Halter J, Martino R, Mohty B, Sucak G, Ullmann AJ, Vázquez L, Ward KN, Engelhard D; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation; Infectious Complications Subcommittee, Spanish Group of Haematopoietic Stem-cell Transplantation. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica. 2011 Aug;96(8):1231-5.
60.    Sucak GT, Aki SZ, Yüzbaşioğlu B, Akyürek N, Yağci M, Bağriaçik U, Haznedar R. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant. Leuk Lymphoma. 2011 Jul;52(7):1281-9.
61.    Yegin ZA, Paşaoğlu H, Aki SZ, Özkurt ZN, Demirtaş C, Yağci M, Acar K, Sucak GT. Pro-oxidative/antioxidative imbalance: a key indicator of adverse outcome in hematopoietic stem cell transplantation.Int J Lab Hematol. 2011 Aug;33(4):414-23.
62.    Haznedar R, Akı ŞZ, Akdemir ÖÜ, Özkurt ZN, Çeneli O, Yağcı M, Sucak GT, Unlü M. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1046-53.
63.    Suyani E, Aki Z, Güzel Ö, Altindal S, Senol E, Sucak G.H1N1 infection in a cohort of hematopoietic stem cell transplant recipients: prompt antiviral therapy might be life saving.Transpl Infect Dis. 2011 Apr;13(2):208-12.
64.    Sucak A, Acar K, Celen S, Danisman N, Sucak GT. Outcome of pregnancies in women with thrombophilic disorders.J Obstet Gynaecol. 2010;30(8):847-51.
65.    Suyanı E, Sucak GT, Akı ŞZ, Yeğin ZA, Özkurt ZN, Yağcı M. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol. 2011 Jun;90(6):685-91.
66.    Beksaç M, Haznedar R, Firatli-Tuğlular T, Özdogu H, AydoĞdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011 Jan;86(1):16-22.
67.    Sucak G, Suyanı E, Özkurt ZN, Yeğin ZA, Aki Z, Yagci M. Abnormal protein bands in patients with multiple myeloma after haematopoietic stem cell transplantation: does it have a prognostic significance? Hematol Oncol. 2010 Dec;28(4):180-4.
68.    Ozyilmaz E, Aydoğdu M, Sucak G, Akı ŞZ, Özkurt ZN, Yeğin ZA, Köktürk N. Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload. Bone Marrow Transplant. 2010 Oct;45(10):1528-33.
69.    Tunçcan OG, Yegin ZA, Ozkurt ZN, Erbaş G, Akı SZ, Senol E, Yağcı M, Sucak G. High ferritin levels are associated with hepatosplenic candidiasis in hematopoietic stem cell transplant candidates.Int J Infect Dis. 2010 Sep;14 Suppl 3:e 104-7.

Adult Hematology

Fields of Study and Interests

• Stem cell transplantation (bone marrow transplantation:

autologous/allogeneic)

• Acute leukemias (AML-ALL)

• Chronic leukemias

• Lymphomas (Hodgkin and non-Hodgkin lymphomas)

• Multiple myeloma

• Bone marrow deficiencies (Myelodysplastic syndrome - aplastic anemia etc.)

• Chronic myeloproliferative diseases (polycythemia vera - essential thrombocytosis - primary

myelofibrosis)

• Anemias / Polycythemias (anemia - excess blood)

• Outpatient and inpatient chemotherapies - immunotherapies - targeted therapies

Education

• Faculty of Medicine – Cerrahpaşa Faculty of Medicine 1999-2005

• Internal Medicine Specialist Training – İstanbul Haseki Training and Research Hospital

20062010

• Hematology Subspecialist Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research

Hospital – Hematology and Stem Cell Transplantation Clinic 2013-2017

• Associate Professor İstanbul Ümraniye Training and Research Hospital 2019

Career

• Assistant Doctor Istanbul Haseki Training and Research Hospital-Internal Medicine Clinic

20062010

• Internal Medicine Specialist Istanbul Esenyurt State Hospital 2010-2012

• Internal Medicine Specialist-Military Service Samsun Military Hospital 2012-2013

• Minor Specialization Training Dr. Abdurrahman Yurtaslan Ankara Oncology Training and

Research Hospital – Hematology and Stem Cell Transplantation Clinic 2013-2017

• Hematology Subspecialist Ankara Gülhane Training and Research Hospital, Hematology and

Stem Cell Transplantation Clinic 2017-2018

• Hematology Subspecialist Istanbul Ümraniye Training and Research Hospital/Hematology

2018-2019

• Associate Professor Istanbul Ümraniye Training and Research Hospital/Hematology 2019-2021

• Associate Professor Maltepe University Faculty of Medicine / Hematology 2021-2024

• Associate Professor Istanbul VM Medical Park Pendik Hospital / Hematology and Stem Cell

Transplantation Clinic 2022-2024

Education & Expertise

• 1997 | Hacettepe University Faculty of Medicine – Medical Degree
• 2003 | Uludağ University Faculty of Medicine – Internal Medicine Specialization
• 2007 | Uludağ University Faculty of Medicine – Hematology Subspecialty

Professional Experience

• 1998 (May – September) | Practitioner, Dr. Salaha Health Center, Rize
• 1998 to 2003 | Research Assistant, Uludağ University Faculty of Medicine, Internal Medicine Department
• 2003 to 2007 | Hematology Subspecialist, Uludağ University Faculty of Medicine, Hematology Division
• 2007 to 2011 | Hematology Specialist, Bursa Ali Osman Sönmez Oncology Hospital (Compulsory Service)
• 2011 to 2013 | Hematology Specialist, Private Anadolu Health Center Bone Marrow Transplant Center, Gebze
• 2014 to 2015 | Assistant Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine
• 2015 to 2020 | Associate Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine
• 2020 to Present | Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine

Courses & Certifications

• Autologous and Allogeneic Stem Cell Transplantation Certificate
• Clinical Phytotherapy Application Certificate
• Flow Cytometry Experience Certificate
• EBMT Stem Cell Transplantation Course

Professional Memberships

• Turkish Medical Chamber
• Turkish Hematology Association (Full Member, No: 893)
• Turkish Therapeutic Apheresis Association (Current President)
• Geriatric Hematology Association
• Hematological Oncology Association
• EBMT (European Bone Marrow Transplantation)

Awards & Recognitions

• 2011 | 6th Turkish Therapeutic Apheresis Congress – Young Researcher Award

Serdar Bedii Omay教授は、血液学および骨髄移植に関する65本以上の学術論文を発表しており、この分野において豊富な経験を有しています。

• 日本の三重大学医学部にて分子血液学の研鑽を積む
• エーゲ大学およびカラデニズ工科大学において血液学の教授を務める
• 1990年より内科および血液学を専門とする
• 学会発表論文112編および学術会議発表34件の執筆・発表実績を持つ

Prof. Dr. Birol Baytan is a respected pediatric hematologist. He focuses on diagnosing and treating childhood cancers, leukemia, anemia, and bleeding disorders. He graduated from Ankara University Medical Faculty in 1992. He completed his specialization at Uludağ University Faculty of Medicine, Department of Child Diseases.

Prof. Baytan has published 15 articles in international journals. He has presented and published 9 full texts at international scientific meetings. He has contributed to 3 books or book chapters. He has also published 8 articles in local journals. These achievements show his strong academic presence in pediatric hematology.